BioCentury | Dec 27, 2019
Product Development

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...
BC Extra | Dec 13, 2019
Company News

Sarepta wins approval for second exon-skipping DMD therapy after disputing FDA decision

FDA reversed an August decision that rebuffed Sarepta’s Vyondys 53 golodirsen, granting accelerated approval to the therapy to treat Duchenne muscular dystrophy in patients amenable to exon 53 skipping. The decision came as a surprise...
BC Extra | Aug 23, 2019
Company News

Management tracks: Erasca, Frequency, PerkinElmer, CytomX, Infinity and more

Erasca Inc. (San Diego, Calif.) promoted Chief Business Officer Gary Yeung to chief operating and financial officer and hired David Chacko to take over the CBO role. Chacko was a principal at investment firm Versant...
BC Extra | Aug 15, 2019
Company News

Management tracks: New executives at Pfizer spinouts Cerevel and SpringWorks

Cerevel Therapeutics LLC (Boston, Mass.) hired Orly Mishan as CBO, a newly created role. She was principal and a founding member of Bain Capital Life Sciences, which launched the Pfizer Inc. (NYSE:PFE) spinout with $350...
BC Extra | Dec 11, 2018
Company News

Management tracks: Grail, EUSA

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Catherine Friedman chairman. She succeeds Bill Rastetter, who will continue as a director. Friedman joined Grail's board last year and also serves on the board of...
BioCentury | Apr 29, 2017
Finance

Earnings on deck

Earnings on deck At least 19 biotechs and pharmas are expected to report earnings this week. (A) Fiscal 2Q; (B) Fiscal 3Q Company Date Pre/post mkt 1Q17 EPS est 1Q16 EPS Expected chg Luminex Corp....
BC Innovations | Dec 8, 2016
Product R&D

Unmarked territory

While the predictive power and standardization of PD-L1 diagnostics is still being hashed out by clinical immuno-oncologists, companies and academics are casting a wide net for better biomarkers to forecast patient responses to checkpoint inhibitors....
BioCentury | Nov 4, 2016
Finance

Earnings on deck

Earnings on deck At least 12 biotechs and pharmas are expected to report earnings this week. (A) Nine-month EPS; (B) Fiscal 2Q; (C) First half EPS Company Date Pre/post mkt 3Q16 EPS est 3Q15 EPS...
BC Extra | Oct 4, 2016
Company News

Management tracks

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) named Brian McNamara CEO of its Consumer Healthcare division. He replaces Emma Walmsley, who is to succeed CEO Andrew Witty next year. McNamara is head of Europe & Americas in the...
BioCentury | Aug 1, 2016
Finance

Gilead's arithmetic problem

Declining HCV sales and lower guidance from Gilead Sciences Inc. (NASDAQ:GILD) shaved about $10 billion off the bellwether's market cap last Tuesday and renewed investor calls for the company to do a splashy deal to...
Items per page:
1 - 10 of 244
BioCentury | Dec 27, 2019
Product Development

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...
BC Extra | Dec 13, 2019
Company News

Sarepta wins approval for second exon-skipping DMD therapy after disputing FDA decision

FDA reversed an August decision that rebuffed Sarepta’s Vyondys 53 golodirsen, granting accelerated approval to the therapy to treat Duchenne muscular dystrophy in patients amenable to exon 53 skipping. The decision came as a surprise...
BC Extra | Aug 23, 2019
Company News

Management tracks: Erasca, Frequency, PerkinElmer, CytomX, Infinity and more

Erasca Inc. (San Diego, Calif.) promoted Chief Business Officer Gary Yeung to chief operating and financial officer and hired David Chacko to take over the CBO role. Chacko was a principal at investment firm Versant...
BC Extra | Aug 15, 2019
Company News

Management tracks: New executives at Pfizer spinouts Cerevel and SpringWorks

Cerevel Therapeutics LLC (Boston, Mass.) hired Orly Mishan as CBO, a newly created role. She was principal and a founding member of Bain Capital Life Sciences, which launched the Pfizer Inc. (NYSE:PFE) spinout with $350...
BC Extra | Dec 11, 2018
Company News

Management tracks: Grail, EUSA

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Catherine Friedman chairman. She succeeds Bill Rastetter, who will continue as a director. Friedman joined Grail's board last year and also serves on the board of...
BioCentury | Apr 29, 2017
Finance

Earnings on deck

Earnings on deck At least 19 biotechs and pharmas are expected to report earnings this week. (A) Fiscal 2Q; (B) Fiscal 3Q Company Date Pre/post mkt 1Q17 EPS est 1Q16 EPS Expected chg Luminex Corp....
BC Innovations | Dec 8, 2016
Product R&D

Unmarked territory

While the predictive power and standardization of PD-L1 diagnostics is still being hashed out by clinical immuno-oncologists, companies and academics are casting a wide net for better biomarkers to forecast patient responses to checkpoint inhibitors....
BioCentury | Nov 4, 2016
Finance

Earnings on deck

Earnings on deck At least 12 biotechs and pharmas are expected to report earnings this week. (A) Nine-month EPS; (B) Fiscal 2Q; (C) First half EPS Company Date Pre/post mkt 3Q16 EPS est 3Q15 EPS...
BC Extra | Oct 4, 2016
Company News

Management tracks

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) named Brian McNamara CEO of its Consumer Healthcare division. He replaces Emma Walmsley, who is to succeed CEO Andrew Witty next year. McNamara is head of Europe & Americas in the...
BioCentury | Aug 1, 2016
Finance

Gilead's arithmetic problem

Declining HCV sales and lower guidance from Gilead Sciences Inc. (NASDAQ:GILD) shaved about $10 billion off the bellwether's market cap last Tuesday and renewed investor calls for the company to do a splashy deal to...
Items per page:
1 - 10 of 244